<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03980691</url>
  </required_header>
  <id_info>
    <org_study_id>20171126V1</org_study_id>
    <nct_id>NCT03980691</nct_id>
  </id_info>
  <brief_title>Effect of Chidamide Combined With CAT-T or TCR-T Cell Therapy on HIV-1 Latent Reservoir</brief_title>
  <official_title>Effect of Chidamide Combined With CAT-T or TCR-T Cell Therapy on HIV-1 Latent Reservoir</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guangzhou 8th People's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Guangzhou 8th People's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To study the safety and effectiveness of the combination of Chidamide with Chimeric Antigen
      Receptor(CAR)-T or T cell receptor(TCR)-T cell therapy on HIV patients based on cART.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Despite the advent of combined antiretroviral therapy (cART), the persistence of viral
      reservoirs remains a major barrier to cure human immunodeficiency virus type 1 (HIV-1)
      infection. Recently, the shock and kill strategy, by which such reservoirs are eradicated
      following reactivation of latent HIV-1 by latency-reversing agents (LRAs), has been
      extensively practiced. It is important to reestablish virus-specific and reliable immune
      surveillance to eradicate the reactivated virus-harboring cells. Some studies have shown that
      Chidamide can highly activate the HIV reservoirs. The VC-CAR-T cells effectively induced the
      cytolysis of LRA-reactivated HIV-1-infected CD4 T lymphocytes isolated from infected
      individuals receiving suppressive cART. Our previous study demonstrated that the special
      features of genetically engineered CAR-T cells make them a particularly suitable candidate
      for therapeutic application in efforts to reach a functional HIV cure. The purpose of this
      study is to evaluate the safety and efficacy of Chidamide together with Chimeric Antigen
      Receptor(CAR)-T or T cell receptor(TCR)-T cell therapy based on cART in HIV-infected adults
      whose plasma HIV has been successfully suppressed after cART.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The control arm includes HIV-infected patients without receiving cellar therapy combined with Chidamide whose HIV-1 has been successfully suppressed after cART.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment-associated adverse events</measure>
    <time_frame>6 Months</time_frame>
    <description>To observe the adverse events of intervention n HIV-infected patients during the study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HIV reservoir</measure>
    <time_frame>6 Months</time_frame>
    <description>To assay the HIV loads in the peripheral blood Mono-nuclear cells and plasma</description>
  </secondary_outcome>
  <other_outcome>
    <measure>HIV-specific immunity</measure>
    <time_frame>6 Months</time_frame>
    <description>The number of HIV-specific CD4,CD8,VC-CAR-T and TCR-T cells after receiving the therapy.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>HIV/AIDS</condition>
  <arm_group>
    <arm_group_label>Chidamide combined with CAR-T or TCR-T cell therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Receiving chidamide combined with CAR-T or TCR-T cell therapy based on based on cART after attaining plasma HIV suppression (plasma HIV RNA &lt;50 cp/ ml) and CD4+ cell count more than 350 cells/ul over 1 year by cART without active HCV or HBV infection or opportunistic infections.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>without intervention</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Not receiving chidamide combined with CAR-T or TCR-T cell therapy but continuing cART after attaining plasma HIV suppression (plasma HIV RNA &lt;50 cp/ml) and CD4+ cell count more than 350 cells/ul over 1 year by cART, without active HCV or HBV infection or opportunistic infections.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Chidamide with CAR-T or TCR-T cell therapy</intervention_name>
    <description>HIV-1 specific therapy</description>
    <arm_group_label>Chidamide combined with CAR-T or TCR-T cell therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. HIV infection confirmed

          2. Receiving cART more than 12 months.

          3. HIV viral-load &lt; 50 copies/ml and CD4 cell count more than 350 cells/ul.

          4. Without serious liver , heart, liver and kidney diseases.

          5. The subjects know about the study and volunteer to attend the research and sign the
             informed consent.

        Exclusion Criteria:

          1. With active HBV or HCV infection, or serious opportunistic infections.

          2. With serious chronic disease such like diabetes, the mental illness,et al

          3. History of suffering from pancreatitis during cART .

          4. Pregnant or breast-fed.

          5. With poor adherence.

          6. Unable to complete follow up.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Weiping Cai, Bachelor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Guangzhou 8th People's Hospital China, Guangdong</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Linghua Li, Doctor</last_name>
    <phone>020-83710825</phone>
    <email>llheliza@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Weiping Cai, Bachelor</last_name>
    <phone>020-83710816</phone>
    <email>gz8hcwp@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Guangzhou 8th People's Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Linghua LI, Doctor</last_name>
      <phone>020-83710825</phone>
      <email>llheliza@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Dotti G, Gottschalk S, Savoldo B, Brenner MK. Design and development of therapies using chimeric antigen receptor-expressing T cells. Immunol Rev. 2014 Jan;257(1):107-26. doi: 10.1111/imr.12131. Review.</citation>
    <PMID>24329793</PMID>
  </reference>
  <reference>
    <citation>Liu C, Ma X, Liu B, Chen C, Zhang H. HIV-1 functional cure: will the dream come true? BMC Med. 2015 Nov 20;13:284. doi: 10.1186/s12916-015-0517-y. Review.</citation>
    <PMID>26588898</PMID>
  </reference>
  <reference>
    <citation>Kuai Q, Lu X, Qiao Z, Wang R, Wang Y, Ye S, He M, Wang Y, Zhang T, Wu H, Ren S, Yu Q. Histone deacetylase inhibitor chidamide promotes reactivation of latent human immunodeficiency virus by introducing histone acetylation. J Med Virol. 2018 Sep;90(9):1478-1485. doi: 10.1002/jmv.25207. Epub 2018 May 25.</citation>
    <PMID>29704439</PMID>
  </reference>
  <reference>
    <citation>Yang W, Sun Z, Hua C, Wang Q, Xu W, Deng Q, Pan Y, Lu L, Jiang S. Chidamide, a histone deacetylase inhibitor-based anticancer drug, effectively reactivates latent HIV-1 provirus. Microbes Infect. 2018 Oct - Nov;20(9-10):626-634. doi: 10.1016/j.micinf.2017.10.003. Epub 2017 Nov 8.</citation>
    <PMID>29126877</PMID>
  </reference>
  <reference>
    <citation>Kobayashi Y, GÃ©linas C, Dougherty JP. Histone deacetylase inhibitors containing a benzamide functional group and a pyridyl cap are preferentially effective human immunodeficiency virus-1 latency-reversing agents in primary resting CD4+ T cells. J Gen Virol. 2017 Apr;98(4):799-809. doi: 10.1099/jgv.0.000716. Epub 2017 Apr 27.</citation>
    <PMID>28113052</PMID>
  </reference>
  <results_reference>
    <citation>Liu B, Zou F, Lu L, Chen C, He D, Zhang X, Tang X, Liu C, Li L, Zhang H. Chimeric Antigen Receptor T Cells Guided by the Single-Chain Fv of a Broadly Neutralizing Antibody Specifically and Effectively Eradicate Virus Reactivated from Latency in CD4+ T Lymphocytes Isolated from HIV-1-Infected Individuals Receiving Suppressive Combined Antiretroviral Therapy. J Virol. 2016 Oct 14;90(21):9712-9724. doi: 10.1128/JVI.00852-16. Print 2016 Nov 1.</citation>
    <PMID>27535056</PMID>
  </results_reference>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>June 7, 2019</study_first_submitted>
  <study_first_submitted_qc>June 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 10, 2019</study_first_posted>
  <last_update_submitted>June 7, 2019</last_update_submitted>
  <last_update_submitted_qc>June 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Guangzhou 8th People's Hospital</investigator_affiliation>
    <investigator_full_name>Linghua LI</investigator_full_name>
    <investigator_title>Vice Chief physician</investigator_title>
  </responsible_party>
  <keyword>Chidamide,CAR cell therapy,TCR cell therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

